Indivior PLC (NASDAQ:INDV) Short Interest Up 21.5% in April

Indivior PLC (NASDAQ:INDV - Get Free Report) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,430,000 shares, a growth of 21.5% from the March 31st total of 2,000,000 shares. Based on an average daily trading volume, of 1,350,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.2% of the company's stock are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on INDV shares. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Piper Sandler decreased their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a report on Thursday, March 6th. Finally, Rodman & Renshaw assumed coverage on shares of Indivior in a report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price objective for the company.

Indivior Trading Down 0.6 %

Shares of NASDAQ:INDV traded down $0.07 during midday trading on Wednesday, reaching $11.63. 15,622 shares of the company were exchanged, compared to its average volume of 983,193. The business's fifty day moving average is $9.87 and its two-hundred day moving average is $10.50. Indivior has a one year low of $7.33 and a one year high of $18.59. The stock has a market cap of $1.60 billion, a PE ratio of -33.18 and a beta of 0.98.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.22 by $0.19. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The company had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. As a group, sell-side analysts expect that Indivior will post 1.22 EPS for the current year.

Institutional Trading of Indivior

Large investors have recently modified their holdings of the company. Deerfield Management Company L.P. Series C increased its holdings in shares of Indivior by 74.4% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock valued at $110,418,000 after acquiring an additional 3,790,518 shares in the last quarter. Claret Asset Management Corp purchased a new stake in Indivior during the 4th quarter worth approximately $9,304,000. CenterBook Partners LP increased its stake in Indivior by 105.5% during the 4th quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock valued at $14,268,000 after purchasing an additional 589,158 shares in the last quarter. Newtyn Management LLC increased its position in shares of Indivior by 62.0% in the 4th quarter. Newtyn Management LLC now owns 1,406,531 shares of the company's stock valued at $17,483,000 after acquiring an additional 538,426 shares during the period. Finally, Marshall Wace LLP raised its stake in Indivior by 659.7% in the 4th quarter. Marshall Wace LLP now owns 506,782 shares of the company's stock worth $6,299,000 after acquiring an additional 440,072 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.